These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35028272)

  • 21. Plasma chitotriosidase enzyme activity as a novel therapeutic monitor for cysteamine treatment in nephropathic cystinosis: A retrospective validation study.
    Veys K; Elmonem MA; van den Heuvel L; Gahl WA; Levtchenko E
    Mol Genet Metab; 2024 May; 142(1):108454. PubMed ID: 38603816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of nephropathic cystinosis with cysteamine.
    Kleta R; Gahl WA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2255-62. PubMed ID: 15500372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.
    Emma F; Hoff WV; Hohenfellner K; Topaloglu R; Greco M; Ariceta G; Bettini C; Bockenhauer D; Veys K; Pape L; Hulton S; Collin S; Ozaltin F; Servais A; Deschênes G; Novo R; Bertholet-Thomas A; Oh J; Cornelissen E; Janssen M; Haffner D; Ravà L; Antignac C; Devuyst O; Niaudet P; Levtchenko E
    Kidney Int; 2021 Nov; 100(5):1112-1123. PubMed ID: 34237326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults.
    Brodin-Sartorius A; Tête MJ; Niaudet P; Antignac C; Guest G; Ottolenghi C; Charbit M; Moyse D; Legendre C; Lesavre P; Cochat P; Servais A
    Kidney Int; 2012 Jan; 81(2):179-89. PubMed ID: 21900880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous cysteamine therapy for nephropathic cystinosis.
    Gahl WA; Ingelfinger J; Mohan P; Bernardini I; Hyman PE; Tangerman A
    Pediatr Res; 1995 Oct; 38(4):579-84. PubMed ID: 8559613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of long-term cysteamine treatment in patients with cystinosis.
    Ariceta G; Giordano V; Santos F
    Pediatr Nephrol; 2019 Apr; 34(4):571-578. PubMed ID: 29260317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effects of starting oral cysteamine treatment in the first 2 months of life on glomerular and tubular kidney function in infantile nephropathic cystinosis.
    Hohenfellner K; Nießl C; Haffner D; Oh J; Okorn C; Palm K; Schlingmann KP; Wygoda S; Gahl WA
    Mol Genet Metab; 2022 Aug; 136(4):282-288. PubMed ID: 35843134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitotriosidase as a Novel Biomarker for Therapeutic Monitoring of Nephropathic Cystinosis.
    Veys KRP; Elmonem MA; Van Dyck M; Janssen MC; Cornelissen EAM; Hohenfellner K; Prencipe G; van den Heuvel LP; Levtchenko E
    J Am Soc Nephrol; 2020 May; 31(5):1092-1106. PubMed ID: 32273301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
    Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Pitfall of White Blood Cell Cystine Measurement to Diagnose Juvenile Cystinosis.
    Bondue T; Kouraich A; Berlingerio SP; Veys K; Marie S; Alsaad KO; Al-Sabban E; Levtchenko E; van den Heuvel L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops.
    Gahl WA; Kuehl EM; Iwata F; Lindblad A; Kaiser-Kupfer MI
    Mol Genet Metab; 2000; 71(1-2):100-20. PubMed ID: 11001803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Swallowing dysfunction in 101 patients with nephropathic cystinosis: benefit of long-term cysteamine therapy.
    Sonies BC; Almajid P; Kleta R; Bernardini I; Gahl WA
    Medicine (Baltimore); 2005 May; 84(3):137-146. PubMed ID: 15879904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in the treatment of cystinosis.
    Schneider JA; Clark KF; Greene AA; Reisch JS; Markello TC; Gahl WA; Thoene JG; Noonan PK; Berry KA
    J Inherit Metab Dis; 1995; 18(4):387-97. PubMed ID: 7494398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up and treatment of adults with cystinosis in the Netherlands.
    Geelen JM; Monnens LA; Levtchenko EN
    Nephrol Dial Transplant; 2002 Oct; 17(10):1766-70. PubMed ID: 12270982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Body growth, upper arm fat area, and clinical parameters in children with nephropathic cystinosis compared with other pediatric chronic kidney disease entities.
    Kluck R; Müller S; Jagodzinski C; Hohenfellner K; Büscher A; Kemper MJ; Oh J; Billing H; Thumfart J; Weber LT; Acham-Roschitz B; Arbeiter K; Tönshoff B; Hagenberg M; Kanzelmeyer N; Pavičić L; Haffner D; Zivicnjak M
    J Inherit Metab Dis; 2022 Mar; 45(2):192-202. PubMed ID: 34989402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nephropathic Cystinosis: Symptoms, Treatment, and Perspectives of a Systemic Disease.
    Bäumner S; Weber LT
    Front Pediatr; 2018; 6():58. PubMed ID: 29594088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephropathic cystinosis: posterior segment manifestations and effects of cysteamine therapy.
    Tsilou ET; Rubin BI; Reed G; Caruso RC; Iwata F; Balog J; Gahl WA; Kaiser-Kupfer MI
    Ophthalmology; 2006 Jun; 113(6):1002-9. PubMed ID: 16603246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice.
    Ariceta G; Santos F; López Muñiz A; Hermida A; Matoses ML; Ventura A; Martin-Moreno PL; González E; Acuña L; Giner E; Vara J
    Clin Kidney J; 2024 Apr; 17(4):sfae049. PubMed ID: 38633840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving the prognosis of nephropathic cystinosis.
    Besouw MT; Levtchenko EN
    Int J Nephrol Renovasc Dis; 2014; 7():297-302. PubMed ID: 25114580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.